1.Contribution of HBV and HCV infection in mortality of B cell non-Hodgkin’s lymphoma subjects
Myagmarjav B ; Anir E ; Delgerbat B ; Khishigjargal B ; Myadagsuren S ; Erdenetsogt D ; Dahgwahdorj Ya ; Davaadorj D ; Naranjargal D
Mongolian Medical Sciences 2020;191(1):19-25
Background:
The correlation between hepatitis B, C viruses (HBV, HCV) and B cell non-Hodgkin’s Lymphoma
(B-NHL) and reducing mortality have been studied extensively worldwide
Objective:
In this study, we aimed to determine the prevalence of HBsAg and anti-HCV positive cases among
B-NHL patients and its influence on the survival rate of these patients (on ≤12 months).
Materials and Methods:
We have done a retrospective analysis on patients who aged over 20 years and newly diagnosed at
the Hematology Center of the First State Hospital between 2015-2018. The patients’ information was
collected according the study ethics. We divided the patients into 2 groups, survival rate less than
12 months (≤12 months) and survival rate more than 13 months (≥13 months), and compared them
regarding age, gender, seroprevalence, and Ann-Arbor stage.
Results:
Overall, 226 patients (107 males and 119 females with average 54.4) were enrolled in the study.
There were 15% HBsAg positive and 41,6% anti-HCV positive cases, while Baatarkhuu et al. (2005)
reported (11.8%, 15.6%; p=0.160, p<0.00001) and Bekhbold et al. (2013) reported (11.1%, 10.6%;
p=0.055, p<0.00001) in apparently healthy population. Moreover, anti-HCV positive cases among
B-NHL patients were higher (p<0.00001) than those (27%) among hepatocellular carcinoma (HCC)
patients and same (p=0.404) with those (39%) among liver cirrhosis patients in Mongolia (Bolormaa
et al., 2009). Furthermore, 72.0% of all subjects in III-IV stages was accounted for HBsAg, anti-HCV
positive group which had ≤12 months, while 52.1% of them was accounted for HBsAg, anti-HCV
positive group which had ≥13 months and was statistical significantly lower (p=0.02).
Conclusion
Anti-HCV and HBsAg positive cases might contribute to survival rate with the B-NHL patients
diagnosed at the III-IV stages. HCV prevalence among B-NHL subjects was significantly higher than
that among the general population prevalence and was same with anti-HCV positive prevalence
among the HCC.
2.The results of acute exacerbation of chronic C hepatitis among Mongolian adults with B-Non-Hodgkin Lymphoma
Myagmarjav B ; Delgerbat B ; Khishigjargal B ; Myadagsuren S ; Oyundelger N ; Altankhuu M ; Erdenetsogt D ; Dahgwahdorj Ya ; Davaadorj D ; Naranjargal D
Mongolian Medical Sciences 2019;189(3):16-21
Background:
Chemotherapy-related acute exacerbation or hepatitis flares related to HCV positive B cell non-Hodgkin’s lymphoma (B-NHL) is one of the significant clinical issues
Material and Method:
We studied anti-HCV incidences among patients newly diagnosed with B-NHL, from 2015 to 2018. Survey data were collecting from medical history, electronic medical record system of First Central Hospital
was acquired and collected according to the research ethics (approved by Ethics Committee of Ministry
of Health, No.4 on June 19, 2017). Also, cases of chemotherapy-related acute exacerbation (AE) for
HCV-RNA positive cases were studied. Student’s t-test or nonparametric statistics were utilized to test
for statistically significant differences in continuous variables, whereas the chi-square or Fisher’s exact
test was used for categorical variables. p<0.05 was considered statistically significant.
Results:
The study showed that 39.5% of 233 cases with B-NHL are anti-HCV positive. Anti-HCV positive prevalence among B-NHL subjects was significantly higher compared to the general population. Chemotherapy-related AE occurred in 21.05% for the anti-HCV positive group and 36.36% for HCV-RNA positive group. Furthermore, before chemotherapy alanine aminotransferase (ALT) median was 15.2 for the group without AE, whereas it was 48.2 for the group with AE (p<0.01).
Conclusions
Our study showed that the prevalence of anti-HCV positive among B-NHL patients was significantly
higher than the general population prevalence. For all cases of AE, HCV-RNA was positive, and these
patients were treated with only chemotherapy without any anti-viral treatment. Anti-viral therapy needs to
be introduced urgently to prevent AE since liver fibrosis is aggravated quickly after AE.